Abstract:Rationale: Gut microbiota plays a crucial role in cancer development and treatment. Studies show that although the gut microbiota is able to promote tumor growth, its presence also improves the efficacy of cancer treatment such as immunotherapy. To date, understanding of the potential impact of the gut microbiota on other treatment modalities such as cancer nanomedicine is still limited. In this study, we aimed to establish the relationship between gut microbiota and cancer nanomedicine, which can potentially open a new path in cancer treatment that combines gut microbiota modulation along with nanotherapeutics. Methods: Mice bearing 4T1 triple-negative breast cancer cells were subjected to gut microbiota modulation by antibiotics (ABX) treatment in the drinking water. Mice given normal water was used for control. The effects of ABX treatment towards gut bacteria was studied by RT-qPCR and 16S next generation sequencing of fecal samples. The mice were then subjected to liposomal doxorubicin (LipoDox) treatment and the amount of nanotherapeutics that accumulated in the tumors was quantified. For therapeutic efficacy, the mice were subjected to ABX treatment and given three injections of LipoDox or saline, while the tumor growth was monitored throughout. Results: Analysis of fecal bacterial content showed that ABX treatment resulted in depletion of gut microbiota. Quantification of LipoDox content revealed significantly increased accumulation in ABX tumor compared to control. Compared to LipoDox treatment alone, we found that combined gut microbiota depletion and LipoDox treatment resulted in augmented long-term anti-tumor efficacy and significantly improved median survival compared to LipoDox only (control vs ABX = 58.5 vs 74 days, p = 0.0002, n = 10 for both groups), with two mice surviving until the end of the experimental end point without experiencing relapse. We also identified the increase in vascular permeability of ABX-treated tumors correlated to for improved therapeutic efficacy and outcome. Conclusion: We showed that gut microbiota depletion led to enhanced tumor vascular permeability, which allowed a larger amount of LipoDox nanoparticles to accumulate in the tumor, leading to better long-term effects. Our results suggest that gut microbiota modulation may be exploited in combination with available nanomedicine-based therapeutics to improve cancer diagnosis, therapeutic efficacy and outcome.

Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy

Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer

Combination gut microbiota modulation and chemotherapy for orthotopic colorectal cancer therapy

Depletion of gut microbiota improves the therapeutic efficacy of cancer nanomedicine

Treatment of colorectal cancer by anticancer and antibacterial effects of hemiprotonic phenanthroline-phenanthroline + with nanomicelle delivery

Antibacterial Fusobacterium Nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐colonized Bacteria And Enhance Immunotherapy Against Colorectal Cancer

Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer

Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer

Gut Fecal Microbiota Transplant in a Mouse Model of Orthotopic Rectal Cancer

Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy

Tumor Colonization and Therapy by Escherichia coli Nissle 1917 Strain in Syngeneic Tumor-Bearing Mice Is Strongly Affected by the Gut Microbiome

The role of gut microbiota in cancer treatment: friend or foe?

Targeting the gut microbiota for cancer therapy

Gut microbiota modulation: a tool for the management of colorectal cancer

Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models

Tumor-targeting engineered probiotic Escherichia coli Nissle 1917 inhibits colorectal tumorigenesis and modulates gut microbiota homeostasis in mice

Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer

The gut microbiome modulate response to immunotherapy in cancer

Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways

Nano-enabled colorectal cancer therapy

Gut microbiota modulation of chemotherapy efficacy and toxicity